Patents by Inventor Charles ZELEN

Charles ZELEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11571494
    Abstract: A method, material, and kit for promoting neutrophils and monocytes to localize at a chronic ulcer site, promoting formation of a multi-layered cell structure in the ulcer site, promoting conversion of monocytes to macrophages, promoting secretion of the patient's own growth factors, promoting tissue proliferation and cell migration, promoting production and cross-linking of collagen at the chronic ulcer site, promoting growth of endothelial cells, promoting angiogenesis that was stalled at the chronic ulcer site, promoting formation of a vascular network and granulation, promoting oxygenation of the chronic ulcer site, and reducing one or more of purulent drainage, erythema, pain, warming, tenderness, induration, and bleeding at the chronic ulcer site.
    Type: Grant
    Filed: December 16, 2020
    Date of Patent: February 7, 2023
    Assignees: Geistlich Pharma AG, University of Southern California
    Inventors: Charles Zelen, David G. Armstrong, Paul Glat, Jarrod Kaufman, Marco Mehr, Lothar Schloesser, Mark Spilker
  • Publication number: 20220023498
    Abstract: A method, material, and kit for promoting neutrophils and monocytes to localize at a chronic ulcer site, promoting formation of a multi-layered cell structure in the ulcer site, promoting conversion of monocytes to macrophages, promoting secretion of the patient's own growth factors, promoting tissue proliferation and cell migration, promoting production and cross-linking of collagen at the chronic ulcer site, promoting growth of endothelial cells, promoting angiogenesis that was stalled at the chronic ulcer site, promoting formation of a vascular network and granulation, promoting oxygenation of the chronic ulcer site, and reducing one or more of purulent drainage, erythema, pain, warming, tenderness, induration, and bleeding at the chronic ulcer site.
    Type: Application
    Filed: December 16, 2020
    Publication date: January 27, 2022
    Applicants: Geistlich Pharma AG, University of Southern California
    Inventors: Charles ZELEN, David G. ARMSTRONG, Paul GLAT, Jarrod KAUFMAN, Marco MEHR, Lothar SCHLOESSER, Mark SPILKER
  • Patent number: 10869949
    Abstract: A method, material, and kit for promoting neutrophils and monocytes to localize at a chronic ulcer site, promoting formation of a multi-layered cell structure in the ulcer site, promoting conversion of monocytes to macrophages, promoting secretion of the patient's own growth factors, promoting tissue proliferation and cell migration, promoting production and cross-linking of collagen at the chronic ulcer site, promoting growth of endothelial cells, promoting angiogenesis that was stalled at the chronic ulcer site, promoting formation of a vascular network and granulation, promoting oxygenation of the chronic ulcer site, and reducing one or more of purulent drainage, erythema, pain, warming, tenderness, induration, and bleeding at the chronic ulcer site.
    Type: Grant
    Filed: April 10, 2020
    Date of Patent: December 22, 2020
    Assignees: Geistlich Pharma AG, University of Southern California
    Inventors: Charles Zelen, David Armstrong, Paul Glat, Jarrod Kaufman, Marco Mehr, Lothar Schloesser, Mark Spilker
  • Publication number: 20200324020
    Abstract: A method, material, and kit for promoting neutrophils and monocytes to localize at a chronic ulcer site, promoting formation of a multi-layered cell structure in the ulcer site, promoting conversion of monocytes to macrophages, promoting secretion of the patient's own growth factors, promoting tissue proliferation and cell migration, promoting production and cross-linking of collagen at the chronic ulcer site, promoting growth of endothelial cells, promoting angiogenesis that was stalled at the chronic ulcer site, promoting formation of a vascular network and granulation, promoting oxygenation of the chronic ulcer site, and reducing one or more of purulent drainage, erythema, pain, warming, tenderness, induration, and bleeding at the chronic ulcer site.
    Type: Application
    Filed: April 10, 2020
    Publication date: October 15, 2020
    Applicants: Geistlich Pharma AG, University of Southern California
    Inventors: Charles ZELEN, David ARMSTRONG, Paul GLAT, Jarrod KAUFMAN, Marco MEHR, Lothar SCHLOESSER, Mark SPILKER